| Novel monoclonal antibody that directly addresses the excess FGF23 activity in patients with XLH |
| Increases serum phosphate levels to within the normal range in children and adults |
| Improves the severity of rickets and other XLH-related outcomes in children with XLH |
| Improves XLH-related symptoms in adults with XLH |
| Well tolerated, with most adverse events being manageable without intervention |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.